Read Gene

Read Gene Interest Expense

The Interest Expense of Read Gene (RDG.WA) as of Oct 17, 2026 is -330,500.00 PLN. In the previous year, Interest Expense was -330,200.00 PLN — a change of 0.09% (lower).

Interest Expense

-330,500.00PLN

YoY

0.09%

Last updated:

Interest Expense of Read Gene is 2025 -330,500.00 PLN. Interest Expense of Read Gene was 2024 -330,200.00 PLN. It decreases by 0.09% lower compared to the previous year.

The Read Gene Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-109,300.00 PLN
Jan 1, 2019
4,600.00 PLN
Jan 1, 2020
-133,900.00 PLN
Jan 1, 2021
-59,800.00 PLN
Jan 1, 2022
-225,500.00 PLN
Jan 1, 2023
-399,000.00 PLN
Jan 1, 2024
-330,200.00 PLN
Jan 1, 2025
-330,500.00 PLN
The Read Gene Interest Expense history
YEARInterest ExpenseYoY
-330,500.00PLN+0.09%
-330,200.00PLN-17.24%
-399,000.00PLN+76.94%
-225,500.00PLN+277.09%
-59,800.00PLN-55.34%
-133,900.00PLN-3,010.87%
4,600.00PLN-104.21%
-109,300.00PLN-18.49%
-134,100.00PLN+10.19%
-121,700.00PLN-6.02%
-129,500.00PLN-0.38%
-130,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA is a biotechnology company based in Szczecin, Poland, operating within the Health Care sector. The company went public via an IPO on February 12, 2009, and is listed under the ticker RDG.WA with ISIN PLRADGN00014. Read Gene SA focuses on medical research and testing, particularly in the fields of chemoprevention, clinical trials, and genetic testing. Its services include specialized tests for breast cancer, colon cancer, and prostate cancer, alongside medical consultancy and DNA testing. The company also provides DNA-related supplements. It operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o., and its major shareholder is GEN-PAT-MED Sp. z o.o. The company's headquarters are located in Szczecin, within the West Pomeranian Voivodeship. Read Gene SA's activities are centered on developing technologies aimed at detecting, preventing, and treating malignant tumors. The company's website is https://read-gene.com/. No additional details regarding founding year, specific products, or financial figures are provided in the source material. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Interest Expense of Read Gene is -330,500.00 PLN in 2025.

Interest Expense of Read Gene changed from -330,200.00 PLN to -330,500.00 PLN, representing a 0.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Read Gene since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Read Gene

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Read Gene